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AbstrAct:
Malignant gliomas are the prototype of highly infiltrative tumors and this 
characteristic is the main factor for the inevitable tumor recurrence and short 
survival after most aggressive therapies. The aberrant communication between 
glioma cells and tumor microenvironment represents one of the major factors 
regulating brain tumor dispersal. Our group has previously reported that the 
tyrosine kinase receptor Tie2/TEK is expressed in glioma cells and brain tumor 
stem cells and is associated with the malignant progression of these tumors. In 
this study, we sought to determine whether the angiopoietin 1 (Ang1)/Tie2 axis 
regulates crosstalk between glioma cells and endothelial cells. We found that Ang1 
enhanced the adhesion of Tie2-expressing glioma and brain tumor stem cells to 
endothelial cells. Conversely, specific small interfering RNA (siRNA) knockdown of 
Tie2 expression inhibited the adhesion capability of glioma cells. Tie2 activation 
induced integrin β1 and N-cadherin upregulation, and neutralizing antibodies 
against these molecules inhibited the adhesion of Tie2-positive glioma cells to 
endothelial cells. In 2D and 3D cultures, we observed that Ang1/Tie2 axis activation 
was related to increased glioma cell invasion, which was inhibited by using Tie2 
siRNA. Importantly, intracranial co-implantation of Tie2-positive glioma cells and 
endothelial cells in a mouse model resulted in diffusely invasive tumors with cell 
clusters surrounding glomeruloid vessels mimicking a tumoral niche distribution. 
Collectively, our results provide new information about the Tie2 signaling in glioma 
cells that regulates the cross-talk between glioma cells and tumor microenvironment, 
envisioning Tie2 as a multi-compartmental target for glioma therapy.
INtrODUctION
Tumor microenvironment plays an important role 
in tumor progression and invasion. Interaction of tumor 
cells with the extracellular matrix and stromal cells is 
crucial for tumor formation including survival, invasion 
and maintenance of tumor-initiating cells [1]. Malignant 
gliomas are the most common type of primary brain tumor, 
and the prognosis for patients with these tumors remains 
dismal [2]. Diffuse, infiltrative invasion of glioma cells 
into surrounding brain tissue results in tumor recurrence 
and contributes to the poor prognosis of patients with 
malignant gliomas [3]. Understanding the molecular 
mechanisms that underlie tumor glioma progression 
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and local invasion of gliomas represents one of the great 
challenges in exploratory cancer research.
The tyrosine kinase receptor Tie2/TEK was initially 
reported as a specific vascular receptor present in both 
normal and tumoral endothelial cells (EC), including 
ECs in astrocytomas, and its levels correlate positively 
with increasing malignancy [4-8]. In these processes, 
Tie2 and its ligands, angiopoietins, are critical to 
angiogenic remodeling [9]. In addition, Tie2 was found 
in hematopoietic stem cells and its function was reported 
as required for postnatal bone marrow hematopoiesis and 
protecting the hematopoietic stem cell compartment from 
myelosuppressive stress [10,11]. We previously showed 
that Tie2 is expressed in glioma cells and brain tumor 
stem cells present in malignant gliomas [12,13]. In the 
current study, we investigated whether the Angiopoietin 1 
(Ang1)/Tie2 axis regulates the crosstalk between glioma 
cells and the tumor microenvironment. Examining in vitro 
and in vivo models of gliomas, we found that glial Tie2 
is involved in enhancing the adhesion of glioma cells to 
ECs, and critically participates in the development of the 
invasive phenotype of gliomas. 
rEsULts
tie2 Activation Enhances the Adhesion of Glioma 
cells to Endothelial cells
Figure 1: tie2 activation increases the adhesion of glioma cells to Ecs. (A) The adhesion of U251.Tie2 cells to HUVECs was 
significantly higher than that of U251.vector cells to HUVECs. Data are presented as the relative ratio of the adhesion of glioma cells to ECs 
(adhesion of U251.vector cells to ECs equals to 1). Fluorescence microphotographs of glioma-HUVEC co-cultures following the removal of 
non-adherent glioma cells are also shown (PKH26 staining; x 50). (B and C) The adhesion of U-87 MG glioma cells (B) and GSC20 BTSCs (C) 
to HUVECs after Ang1 or Ang2 treatment. Data are the relative ratio of the adhesion of glioma cells to ECs (adhesion of untreated glioma cells 
to ECs equals to 1). Fluorescence microphotographs of glioma-HUVEC co-cultures taken following the removal of non-adherent glioma cells 
are also shown (B; PKH26 staining;x 25). (D) Adhesion studies of Tie2-negative U-373 MG cells after Ang1 treatment. Data are the relative 
ratio of the adhesion of glioma cells to ECs (adhesion of untreated glioma cells to ECs equals to 1). Data in each panel are the means ± SD 
from three independent experiments performed in triplicate. *, P < .05; **, P < .001; #, P > .05. E, U-87 MG cells were transfected with Tie2 
siRNA or control siRNA and exposed to Ang1 before adhesion assay. Data are the relative ratio of the adhesion of glioma cells to ECs (adhesion 
of U-87 MG cells transfected with control siRNA and exposed to vehicle equals to 1). The means ± SD from three independent experiments 
performed in triplicate are shown. *, P < 0.05. Fluorescence microphotographs show the adhesion of U-87 MG glioma cells to endothelial 
cultures after the indicated treatments (PKH26 staining; original magnification x 100). 
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To characterize the role of Tie2 activation in glioma 
cell–EC interaction, we used a co-culture system in which 
the adhesion of fluorescent dye–labeled glioma cells to 
an EC monolayer was quantified by flow cytometry. We 
found that the adhesion of U251.Tie2 cells to ECs was 
more than two-fold higher than the adhesion of U251.
vector cells to ECs (Figure 1A). We further analyzed the 
adhesion properties of endogenous Tie2-expressing cells, 
U-87 MG glioma cells and GSC20 BTSCs [13]. Ang1 
significantly stimulated adhesion of both Tie2-expressing 
glioma cells and BTSCs to ECs (Figures 1B and C). Of 
importance, similar experiment performed in the presence 
of Ang2, a context-dependent Tie2 ligand, did not modify 
the adhesive properties of glioma cells to ECs (Figure 1B). 
We tested the specificity of action of Ang1 on Tie2 
receptor by performing two different experiments. First, 
treating Tie2-negative U-373 MG cells [13] with Ang1 
did not modify their adhesion to ECs (Figure 1D). Second, 
treatment with Tie2 siRNA significantly abolished Ang1-
induced adhesion of U-87 MG cells to ECs (Figure 1E). 
These results indicate that the Ang1/Tie2 axis plays a 
major role in mediating the adhesion of glioma cells and 
BTSCs to ECs.
tie2 Enhances Adhesion of Glioma cells to 
Endothelial cells by upregulating integrin 1 and 
N-cadherin 
To determine which molecules are involved in Tie2-
mediated adhesion of glioma cells to ECs, we performed 
cell adhesion experiments in the presence of EDTA 
and found a significant decrease in the number of Tie2-
positive glioma cells that adhered to EC monolayers, 
suggesting the contribution of calcium-dependent 
adhesion molecules (Figure 2A). Because cell-to-cell 
adhesion involves the interaction of adhesion molecules 
Figure 2: tie2 activation results in upregulation of adhesion molecules in gliomas. (A) The adhesion of U251.vector and U251.
Tie2 cells to ECs was performed in the presence of EDTA. *, P < .05. (B) The Ang1/Tie2 axis regulates N-cadherin expression. U-87 MG 
cells treated with Ang1, Ang2, or vehicle, and isogenic U251.vector and U251.Tie2 cells were immunostained with anti-human N-cadherin 
antibody and analyzed with flow cytometry. The results from one of three independent experiments are shown. Leftmost diagram represents 
cells stained with isotype immunoglobulin G (IgG). (C) The adhesion of U251.Tie2 cells or U251.vector cells to ECs was performed in the 
presence of neutralizing antibodies against N-cadherin (C) or integrin β1 (D). IgG was used as a control, and antibodies against VEGF were 
used for specificity. Data are the relative ratio of the adhesion of glioma cells to ECs (adhesion of U251.vector cells to ECs in the presence of 
Mock (C) or IgG (D) equals to 1). The means ± SD from three independent experiments performed in triplicate are shown. *, P < .05, **; P < 
.001; #, P > .05. 
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on the cell surface, we then used flow cytometry to analyze 
the cell-surface expression of N-cadherin. U251.Tie2 
cells expressed significantly higher levels of N-cadherin 
than U251.vector cells (Figure 2B). Similarly, U-87 MG 
cells expressed higher levels of surface N-cadherin after 
Ang1 treatment (Figure 2B), as confirmed by Western blot 
analysis (Supplementary Figure 1). However, treating 
U-87 cells with Ang2 did not significantly modify the 
expression of cell-surface N-cadherin (Figure 2B). We 
used quantitative RT-PCR to compare the mRNA levels of 
N-cadherin, E-cadherin, α-catenin, and β-catenin in U251.
vector versus U251.Tie2 cells and U-87 MG cells after 
treatment with Ang1 or vehicle. We did not observe any 
significant modification in the mRNA levels of N-cadherin, 
α-catenin, or β-catenin (E-cadherin expression was not 
detectable) in relation to Tie2 activation, suggesting 
a post-transcriptional regulation of these molecules 
(Supplementary Figure 2). 
To determine whether N-cadherin is involved in 
Tie2-mediated glioma cell adhesion, we incubated U251.
Tie2 cells with a neutralizing antibody against N-cadherin 
before and during their co-culture with ECs. We found that 
the adhesion of U251.Tie2 cells to ECs in the presence 
of neutralizing antibodies against N-cadherin completely 
abolished the Tie2-mediated adhesion to ECs (Figure 2C). 
To determine whether the upregulation of integrin ß1 is 
involved in Tie2-mediated glioma cell-to-EC adhesion, 
we performed adhesion experiments in the presence of 
an integrin ß1–neutralizing antibody. We observed a 
significant decrease in the adhesion of U251.Tie2 glioma 
cells to ECs. Suggesting specificity of these results, a 
neutralizing antibody for VEGF, a molecule involved in 
cell-to-cell interaction [14], did not modify the adhesive 
properties of Tie2-expressing glioma cells (Figure 2D). 
These data suggested that both N-cadherin and integrin ß1 
play major roles in the Tie2-mediated adhesion of glioma 
cells to ECs. 
tie2 Activation stimulates Glioma cell Invasion 
in Vitro
Figure 3: tie2 activation enhanced the invasive properties of glioma cells. (A-C) Invasion assays were performed in Tie2-
expressing U-87 MG cells (A) and NSC20 BTSCs upon Ang1 exposure (C) and in isogenic-derived U-251 MG cells (B). Data are the relative 
ratio of invasive glioma cells with active Tie2 compared to invasive vehicle-treated glioma cells (A and C) or U251.vector cells (B) (equal to 1). 
The means ± SD from three independent experiments performed in triplicate are shown. Representative microphotographs show glioma cells 
invading Matrigel under the indicated culture conditions (original magnification x 50). Tie2 expression was downregulated by transfecting the 
cells with Tie2 siRNA before invasion assay. *, P < .05, **, P < .01. 
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Because our data suggest that Tie2 activation 
increased cell adhesion properties and N-cadherin and 
integrin ß1 expression, and alterations in these two 
molecules have been implicated in the invasive phenotype 
of malignant gliomas [15,16], we next sought to determine 
whether Tie2 activation modulates glioma cell invasion. 
Invasion assay revealed that the number of U251.Tie2 cells 
that migrated through the Matrigel was more than 3-fold 
the number of U251.vector cells that migrated through 
the Matrigel (Figure 3A). Similarly, cells expressing 
endogenous Tie2 showed a higher degree of invasion 
when treated with Ang1. Thus, Ang1-treated U-87 MG 
cells invaded the basement membrane about three-fold 
more than vehicle-treated U-87 MG cells. These results 
were confirmed by studying the role of Tie2-positive 
BTSCs, GSC20, in invasion. Thus, the number of GSC20 
cells migrated was two-fold higher when the cultures were 
exposed to Ang1 than to the vehicle. Together these data 
suggested a role of Ang1/Tie2 in invasion of glioma cells.
To further clarify the role of Tie2 in the invasive 
phenotype, we used specific siRNA to knock down Tie2 
expression. Tie2 downmodulation resulted in the partial 
rescue of the invasive phenotype in both Ang1-treated 
U-87 MG cells (Figure 3D) and U251.Tie2 cells (Figure 
3E). Moreover, neutralizing antibodies against integrin β1 
inhibited the Tie2-mediated invasion of both glioma cell 
lines. These data suggest that the Ang1/Tie2/integrin β1 
axis contributes to glioma cell invasion in vitro.
To better mimic the in situ tumor confining and allow 
the contact with 3D matrix, we generated 3D cultures of 
U251.vector and U251.Tie2 cells in an enriched collagen 
I matrix since collagen I is one of the major components 
of the extracellular matrix of gliomas and the activation 
of Tie2 resulted in increased adhesion to this extracellular 
component [12]. We observed that the 3D U251.Tie2 
spheroids acquired an invasive phenotype consisting 
on a single-cell migration pattern from the periphery of 
the spheroids. This characteristic pattern was observed 
Figure 4: tie2 activation increase tumor cell invasion of 3D matrix. (A) Cell spheroids generated from U251.vector or U251.Tie2 
cells invaded collagen-enriched Matrigel after 11 days of culture. Phase contrast pictures showed the invasive front of these spheroids (close-
up of the boxed areas). (B) U-87 MG cell spheroids were cultured in 3D collagen gel with or without incubation of 500ng/ml Ang1 (upper 
panel). U-87 MG cell were also treated with control or Tie2 siRNA before incorporated into 3D collagen gel and incubation of Ang1 (lower 
panel). Phase contrast pictures showed cell invasion of collagen matrix on day 3. The distance from invasive front to the edge of U-87 MG cell 
spheroids was measured and compared in different treatment groups (C).
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as soon as 72 hrs of the initiation of the 3D culture and 
was maintained by 11 days, the last time point examined. 
However, cells from 3D U251.vector spheroids did not 
displayed significant migration through the matrix (Figure 
4A). Confirmatory experiments were performed using 
U-87 MG-derived spheroids. U-87 MG cells were pre-
incubated with Ang1 and then spheroids were cultured in a 
collagen I-enriched matrix containing Ang1. We observed 
an accelerated rate of migration of Ang1-stimulated U-87 
MG cells through the matrix. This response was partially 
abrogated by knocking-down Tie2 expression (Figures 
4B and C). These results corroborated an essential role of 
Tie2 in brain tumor dispersal in vitro. 
Glioma tie2 Expression Increases tumorigenesis 
characterized by an Invasive Phenotype in Vivo
To determine whether Tie2-mediated changes in 
glioma phenotype modulates the neoplastic characteristics 
of these tumors in vivo, we injected U251.vector or U251.
Figure 5: role of the interaction of tie2+ glioma cells with Ecs in gliomagenesis in vivo. (A) Table showing the number of mice 
injected with the indicated cells and the incidence of tumor formation. Data are the combined results of two independent experiments. P values 
for the comparison of tumor incidence are shown (F fisher test). (B) U251.vector or U251.Tie2 cells were injected alone or with ECs into the 
brains of immunocompromised mice.  Hematoxylin and eosin–stained sections of the resulting xenografts are shown. Black arrows indicate the 
approximate limits of the tumors (upper panels; x 100). Note the infiltrative/multifocal component of tumors derived from Tie2-positive cells 
injected with ECs. Close-up of the boxed areas in lower panels. (C) Tie2 and Nestin double immunostaining performed in a GSC20-derived 
intracranial xenograft sample. Arrows indicate Tie2 and Nestin co-localization.
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Tie2 cells into the brains of immunodeficient mice, and 
then we sacrificed the animals approximately 20 days 
after cell implantation, and analyzed their brains for the 
presence of tumors. Although we observed an increase of 
tumor formation with co-injection of U251.vector cells 
with ECs (33%), this number was significantly higher 
when we co-injected the mice with U251.Tie2 cells and 
ECs: 11 of 14 (79%) animals developed intracranial tumors 
(Figure 5A). Intriguingly, U251.Tie2 and EC–derived 
tumors had different features than U251.vector and EC–
derived tumors (Figure 5B). Thus, glioma cells migrated 
farther from the site of injection, resulting in multifocal 
tumors that surrounded vascular structures. Furthermore, 
and as a novel finding, this pro-tumorigenic force is 
enhanced and modulated towards an invasive phenotype 
in the presence of neoplastic glial cells expressing 
Tie2. To further characterize the glioma Tie2+ cells, we 
analyzed a BTSC-derived intracranial xenografts. In this 
animal model, Tie2 positive cells co-stained positive for 
Nestin expression (30% ± 8% of Nestin+ cells) suggesting 
a precursor origin (Figure 5C) [17]. Together our data 
suggest that Tie2 plays a non-previously described key 
role in the crosstalk between the neoplastic glial cells and 
the vascular compartment that, ultimately, modulates the 
invasive properties of those tumors. 
DIscUssION
In this report we provide new information on the 
role of Tie2 in glioma and brain tumor stem cells. Our 
data showed that Tie2 activity in glioma cells and BTSCs 
was related to enhanced adhesion to the endothelial 
compartment with subsequent increase of their invasion 
capability. We also found that injecting Tie2-positive cells 
together with ECs into the brains of immunocompromised 
animals resulted in the development of invasive, multifocal 
tumors that surrounded vascular structures. These data are 
relevant because the invasive phenotype of GBMs is one 
of the main underlying cause of their refractoriness to 
conventional treatment and responsible for the invariable 
recurrence after therapy [18].
Our study is continuation of our previous work 
on the Tie2-mediated regulation of integrin β1 and the 
adhesion to several components of the extracellular 
matrix [12]. Integrin-mediated cell substratum adhesion 
and migration often occur simultaneously with cadherin-
based cell-to-cell adhesion [19-22]. In gliomas, integrin 1 
has been reported to be involved in adhesion, migration, 
and invasion [23, 24]. Moreover, N-cadherin expression 
levels have been reported to be related to the progression 
of the malignant phenotype [25]. Here we found that 
Tie2 activity upregulates N-cadherin in the membrane 
of glioma cells that function to effectively mediate the 
cellular interactions with the tumor microenvironment. 
Several lines of evidence support an orchestrated 
regulation between cadherin- and integrin-mediated 
systems [19, 26]. These cellular interactions should occur 
following a temporal and spatial regulation of cell-to-cell 
and cell-to-substrate adhesion properties. The fact that 
Tie2 activation results in cell-to-cell, as well as cell-to-
substrate adhesion, strongly suggests that Tie2 signaling 
is one of the key interactors in the tight and coordinated 
regulation of these two processes.
Implications of the existence of BTSCs [17, 27] 
include that these cells are associated with the vasculature 
in brain tumors constituting the so-called perivascular 
niche [28]. A corollary of this tenet is the hypothesis that 
interaction of BTSCs with ECs mediates chemoresistance 
of cancer cells. Although the interaction of BTSCs with 
ECs has been implicated in maintaining the self-renewing 
and undifferentiated state of BTSCs [28], little is known 
about the mechanism of this critical crosstalk. In the 
current study, we found that Ang1 significantly enhanced 
the adhesion of Tie2-positive BTSCs to ECs. These 
results together with our earlier findings regarding the 
contribution of Tie2 signaling to the chemoresistance of 
BTSCs [13, 29] might indicate that Tie2 interacts with 
BTSCs and contributes to the perivascular, chemoresistant 
niche. Further studies should ascertain to which extent 
the roles of Tie2 in mediating BTSC adhesion to ECs 
and increasing chemoresistance are independent or 
interdependent signaling pathways.
 Preventing gliomas from developing an invasive 
phenotype is one of the main challenges involved in 
blocking glioma recurrence and improving outcome. 
In the current study, we observed that injecting Tie2-
positive glioma cells together with ECs resulted in the 
formation of more tumors that, in turn, tended to be more 
aggressive than Tie2-negative tumors. Thus, although the 
role of the tumor microenvironment in modulating the 
neoplastic phenotype has been previously reported [28], 
the molecular mechanisms regulating this relationship 
are still under investigation. The work presented here 
demonstrates the key role of Tie2 in the influence of the 
tumor/microenvironment cross-talking on the malignant 
phenotype of gliomas. 
In the fullness of time, our data may have important 
overtones for the therapy of malignant gliomas. Placing 
Tie2 as a landscape regulator and therefore, as one 
of the main interactor in the complexity of the tumor 
microenvironment regulation, suggests that therapeutic 
targeting of Tie2 would be a potent anti-multicompartment 
approach.
MAtErIALs AND MEtHODs
cell culture
U-87 MG and U-251 MG human glioma cell lines 
(American Type Culture Collection) were maintained 
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as previously described [12]. Human Umbilical Vein 
Endothelial Cells (HUVECs; Clonetics) were used before 
passage 10 and maintained according to the provider’s 
instructions. NSC20/GSC20 neurospheroid cultures were 
established from a human glioblastoma multiforme (GBM) 
surgical specimen and maintained as described previously 
[17]. Tie2-overexpressing U-251 MG (U251.Tie2) cells 
and vector-transfected U-251 MG (U251.vector) cells 
were previously generated [12]. We purchased Ang1 and 
Ang2 from R&D Systems. 
small Interfering rNA Oligonucleotide 
transfection
Human glioma cells were plated in 60-mm dishes (3 x 
105 cells per dish). After 18 hours, we used Lipofectamine 
2000 (Invitrogen) to transfect the cells with 40 nM Tie2 
small interfering RNA (siRNA) or scrambled siRNA 
oligonucleotides (Santa Cruz Biotechnology) according 
to Invitrogen’s instructions as previously reported and 
validated [12-13]. 
Glioma-to-Endothelial cell Adhesion Assay
HUVECs were seeded onto 24-well plates (1 x 
105 cells/well) 48 hours before adhesion assay. Glioma 
cells were labeled with PKH26 red dye (2 x 10–6 M; 
Sigma) according to the manufacturer’s instructions, 
resuspended in serum-free medium, and seeded onto 
HUVEC monolayers at a 5:1 glioma cell–to–EC ratio, and 
incubated at 37ºC. After 15 minutes, we removed non-
adherent glioma cells and used fluorescence microscopy 
(Axiovert 200; Carl Zeiss MicroImaging Inc) to visualize 
the adhesion of glioma cells to ECs. We then used a 0.05% 
trypsin/0.02% EDTA (w/v) solution to disrupt aggregates 
and provide a single-cell suspension for glioma cell 
quantification by flow cytometry (FACS Calibur; Becton 
Dickinson). Data were processed using CellQuest Pro 
software (BD Biosciences).
For calcium-chelating experiments, we pre-
incubated glioma cells with 1 mM EDTA for 20 minutes 
and we added 1mM neutralizing antibodies for 15 minutes 
before and during co-culture with ECs: anti-N-cadherin 
(clone GC4; 1:30 dilution; Sigma), anti-integrin ß1 
antibody (clone 6S6; 10 µg/ml; Chemicon International), 
and anti-human VEGF antibody (MAB293; 1µg/ml; 
R&D Systems). Mouse IgG1 (MAB002) or IgG2B isotypes 
(MAB004; R&D Systems) were used as controls.
Flow cytometric Analysis
We used flow cytometry (FACSCalibur) to measure 
cell-surface N-cadherin expression. We used 5 mM EDTA 
to detach 1 x 106 glioma cells and incubated the cells 
with mouse anti-human N-cadherin antibody (clone GC4; 
1:900 dilution; Sigma), or the same amount of mouse IgG1 
(R&D Systems) as negative control at 4°C for 1 hour and 
with Alexa 488–conjugated anti-mouse antibody (1:100 
dilution; Invitrogen) for 15 minutes at room temperature. 
Matrigel Invasion Assay
For invasion assay, we coated transwells (ThinCert 
TC Inserts, 8.0-µm pore size; USA Scientific) in 24-well 
plates with 0.3 mg/ml Matrigel (BD Biosciences) and 
allowed them to adjust to room temperature for 2 hours. 
Glioma cells (1 x 105) were washed with serum-free 
medium, suspended in 250 µl serum-free medium, and 
seeded onto the Matrigel-coated transwells. 600 µl DMEM/
F12 supplemented with 2% fetal bovine serum was added 
to the lower chambers. When indicated, cells were pre-
incubated with a neutralizing antibody against integrin ß1 
(clone 6S6; 10 µg/ml; Chemicon International), or IgG1 
as isotype control (R&D System) for 20 minutes at 37ºC. 
Cells were then plated in the transwells in the presence of 
anti-integrin ß1 antibody. After incubating overnight, cells 
on the top of the inserts were removed. Inserts were then 
fixed with methanol and stained with 0.5% crystal violet 
(Sigma-Aldrich) for 10 minutes, and relative number of 
cells was quantified by measuring absorbance at 570 nm.
3D glioma cultures and invasion assay
To generate glioma cell spheres, 1×104 glioma cells 
suspended in 100µl DMEM/F12 medium were seeded 
into a 96-well plate coated with 1% agarose gel and 
incubated overnight. 96-well plates were coated with 
collagen-enriched Matrigel, which consisted on mixing 
on ice the neutralized collagen I (R&D systems) and 
growth factor reduced Matrigel (BD Bioscience) such that 
the final collagen concentration was 1.6 mg/ml. Then, the 
wells were incubated for 20 minutes in 37°C for gelling. 
Glioma cell spheres were transferred into these collagen-
enriched Matrigel-coated 96-well plates, and subsequently 
overlaid with another layer of 50µl neutralized collagen. 
After solidification of the upper layer for 15 minutes, 3D 
cultures were incubated with 150µl serum-free DMEM/
F12 medium. When indicated, 500ng/ml Ang1 was both 
incorporated into the collagen solution before gelling and 
supplemented into the culture medium. For assessment 
of invasion, we periodically analyzed by microscopy the 
presence of invading individual cells and we measured 
the major invasive front from the spheroid (completely 
surrounded by the matrix and not in contact with the walls 
of the well at any point).
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Animal studies
Animal studies were performed in veterinary 
facilities at The University of Texas M. D. Anderson 
Cancer Center in accordance with institutional guidelines. 
To study whether Tie2 activation in crosstalk with the ECs 
impacts tumorigenicity, we injected 1 x 106 U251.vector 
or U251.Tie2 cells alone or in a suspension containing 2 
x 105 HUVECs into the caudate nuclei of 4- to 6-week-
old female athymic mice (Harlan-Sprague Dawley, Inc.) 
as previously described [30]. To study Tie2 expression 
in brain tumor stem cell (BTSC)-derived intracranial 
xenografts, we implanted 5 x 105 GSC20 cells into the 
caudate nuclei of 4- to 6-week-old female athymic mice 
and sacrificed the animals when showing generalized 
or localized symptoms of toxicity were sacrificed. We 
removed the brains, fixed in 4% formalin, and embedded 
them in paraffin. Hematoxylin and eosin–stained coronal 
sections were evaluated for evidence and characterization 
tumors.
Immunohistochemistry and Immunofluorescence 
studies
For double immunofluorescence studies, tissue 
sections were blocked with 10% goat serum following 
heat-induced antigen retrieval and then incubated with anti-
Tie2 antibody (C-20; 1:50; Santa Cruz Biotechnology) and 
anti-Nestin (MAB5326; 1:200, Chemicon International). 
Texas red– and fluorescein isothiocyanate–conjugated 
secondary antibodies (Santa Cruz Biotechnology), 
respectively, were used for 1 hour at room temperature. 
statistical Analyses
For quantitative data analysis, the results were 
plotted as the mean ± SEM. Statistical analysis was 
performed using GraphPad Prism version 3.0a (GraphPad 
Software Inc.). Statistical significance was determined 
using Student’s t tests, or for multiple comparisons using 
two-way analysis of variance (ANOVA). For enumeration 
data analysis, the results were plotted as the frequencies. 
Statistical significance between groups was determined 
using chi-square analysis.
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